Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation
- PMID: 17483121
- DOI: 10.1093/toxsci/kfm100
Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation
Abstract
Physiologically based pharmacokinetic (PBPK) models are used in mode-of-action based risk and safety assessments to estimate internal dosimetry in animals and humans. When used in risk assessment, these models can provide a basis for extrapolating between species, doses, and exposure routes or for justifying nondefault values for uncertainty factors. Characterization of uncertainty and variability is increasingly recognized as important for risk assessment; this represents a continuing challenge for both PBPK modelers and users. Current practices show significant progress in specifying deterministic biological models and nondeterministic (often statistical) models, estimating parameters using diverse data sets from multiple sources, using them to make predictions, and characterizing uncertainty and variability of model parameters and predictions. The International Workshop on Uncertainty and Variability in PBPK Models, held 31 Oct-2 Nov 2006, identified the state-of-the-science, needed changes in practice and implementation, and research priorities. For the short term, these include (1) multidisciplinary teams to integrate deterministic and nondeterministic/statistical models; (2) broader use of sensitivity analyses, including for structural and global (rather than local) parameter changes; and (3) enhanced transparency and reproducibility through improved documentation of model structure(s), parameter values, sensitivity and other analyses, and supporting, discrepant, or excluded data. Longer-term needs include (1) theoretical and practical methodological improvements for nondeterministic/statistical modeling; (2) better methods for evaluating alternative model structures; (3) peer-reviewed databases of parameters and covariates, and their distributions; (4) expanded coverage of PBPK models across chemicals with different properties; and (5) training and reference materials, such as cases studies, bibliographies/glossaries, model repositories, and enhanced software. The multidisciplinary dialogue initiated by this Workshop will foster the collaboration, research, data collection, and training necessary to make characterizing uncertainty and variability a standard practice in PBPK modeling and risk assessment.
Similar articles
-
PBPK models in risk assessment--A focus on chloroprene.Chem Biol Interact. 2007 Mar 20;166(1-3):352-9. doi: 10.1016/j.cbi.2007.01.016. Epub 2007 Feb 8. Chem Biol Interact. 2007. PMID: 17324392
-
Development and specification of physiologically based pharmacokinetic models for use in risk assessment.Regul Toxicol Pharmacol. 2008 Feb;50(1):129-43. doi: 10.1016/j.yrtph.2007.10.012. Epub 2007 Nov 6. Regul Toxicol Pharmacol. 2008. PMID: 18077066 Review.
-
Evaluation of physiologically based pharmacokinetic models for use in risk assessment.J Appl Toxicol. 2007 May-Jun;27(3):218-37. doi: 10.1002/jat.1225. J Appl Toxicol. 2007. PMID: 17299829 Review.
-
Approaches for applications of physiologically based pharmacokinetic models in risk assessment.J Toxicol Environ Health B Crit Rev. 2008 Aug;11(7):519-47. doi: 10.1080/10937400701724337. J Toxicol Environ Health B Crit Rev. 2008. PMID: 18584453 Review.
-
Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach.Toxicol Appl Pharmacol. 2009 Nov 15;241(1):36-60. doi: 10.1016/j.taap.2009.07.032. Epub 2009 Aug 4. Toxicol Appl Pharmacol. 2009. PMID: 19660485
Cited by
-
Development, testing, parameterisation, and calibration of a human PBK model for the plasticiser, di (2-ethylhexyl) adipate (DEHA) using in silico, in vitro and human biomonitoring data.Front Pharmacol. 2023 Mar 23;14:1165770. doi: 10.3389/fphar.2023.1165770. eCollection 2023. Front Pharmacol. 2023. PMID: 37033641 Free PMC article.
-
Development, testing, parameterisation, and calibration of a human PBPK model for the plasticiser, di-(2-ethylhexyl) terephthalate (DEHTP) using in silico, in vitro and human biomonitoring data.Front Pharmacol. 2023 Feb 20;14:1140852. doi: 10.3389/fphar.2023.1140852. eCollection 2023. Front Pharmacol. 2023. PMID: 36891271 Free PMC article.
-
An Overview of Physiologically-Based Pharmacokinetic Models for Forensic Science.Toxics. 2023 Jan 28;11(2):126. doi: 10.3390/toxics11020126. Toxics. 2023. PMID: 36851001 Free PMC article. Review.
-
A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs.Front Bioinform. 2021 Sep 3;1:731340. doi: 10.3389/fbinf.2021.731340. eCollection 2021. Front Bioinform. 2021. PMID: 36303796 Free PMC article.
-
Evaluation of a rapid, generic human gestational dose model.Reprod Toxicol. 2022 Oct;113:172-188. doi: 10.1016/j.reprotox.2022.09.004. Epub 2022 Sep 16. Reprod Toxicol. 2022. PMID: 36122840 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
